Genfleet Therapeutics (Shanghai) Inc. made a successful return to the Hong Kong Stock Exchange with its IPO, raising $234 million. Shares surged 106% above the listing price on debut, reflecting strong investor appetite. This infusion of capital is expected to accelerate Genfleet's pipeline development and global expansion in biopharmaceuticals, particularly in oncology and immunotherapy. The listing also highlights renewed foreign investment interest in Asian biotech firms amid ongoing market recalibrations.